Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

Emanuele Vita; Alessio Stefani; Mariantonietta Di Salvatore; Marco Chiappetta; Filippo Lococo; Stefano Margaritora; Giampaolo Tortora; Emilio Bria

doi:10.3390/jcm10112290

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

Emanuele Vita, Alessio Stefani, Mariantonietta Di Salvatore, Marco Chiappetta, Filippo Lococo, Stefano Margaritora, Giampaolo Tortora, Emilio Bria

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	Journal of Clinical Medicine
Volume	10
DOI	https://doi.org/10.3390/jcm10112290
Stato di pubblicazione	Pubblicato - 2021

Keywords

immunotherapy
malignant pleural mesothelioma
target therapy

Accesso al documento

10.3390/jcm10112290

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

@article{f364aaaf67c945ccb2ba2677a90cfd55,

title = "Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma",

abstract = "Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.",

keywords = "immunotherapy, malignant pleural mesothelioma, target therapy, immunotherapy, malignant pleural mesothelioma, target therapy",

author = "Emanuele Vita and Alessio Stefani and {Di Salvatore}, Mariantonietta and Marco Chiappetta and Filippo Lococo and Stefano Margaritora and Giampaolo Tortora and Emilio Bria",

year = "2021",

doi = "10.3390/jcm10112290",

language = "English",

volume = "10",

pages = "N/A--N/A",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

}

TY - JOUR

T1 - Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

AU - Vita, Emanuele

AU - Stefani, Alessio

AU - Di Salvatore, Mariantonietta

AU - Chiappetta, Marco

AU - Lococo, Filippo

AU - Margaritora, Stefano

AU - Tortora, Giampaolo

AU - Bria, Emilio

PY - 2021

Y1 - 2021

N2 - Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.

AB - Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.

KW - immunotherapy

KW - malignant pleural mesothelioma

KW - target therapy

KW - immunotherapy

KW - malignant pleural mesothelioma

KW - target therapy

UR - http://hdl.handle.net/10807/245995

U2 - 10.3390/jcm10112290

DO - 10.3390/jcm10112290

M3 - Article

SN - 2077-0383

VL - 10

SP - N/A-N/A

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

ER -

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo